KELLY RALPH DAVID
Known title: DirectorCIK: 0001632674
Associated companies
Transaction History
| ACHC | ▲ Buy | Grant | 6,331 | $0 | 5/6/2026 | View on chart |
| ACHC | ▲ Buy | Grant | 7,032 | $0 | 5/29/2025 | View on chart |
| ACHC | ▲ Buy | Grant | 4,923 | $0 | 5/29/2025 | View on chart |
| ACHC | ▲ Buy | Grant | 2,414 | $0 | 5/23/2024 | View on chart |
| ACHC | ▲ Buy | Grant | 2,229 | $0 | 5/18/2023 | View on chart |
| ACHC | ▲ Buy | Grant | 1,351 | $97K | 5/18/2023 | View on chart |
| ACHC | ▲ Buy | Grant | 2,078 | $0 | 7/21/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Acadia Healthcare Sets Q3 2026 Earnings Date
Acadia Healthcare announced the date for its third-quarter 2026 earnings release. This update provides a timeline for the next major financial report from the company. The stock is currently trading within its 52-week range of $11.43 to $35.83, with an average analyst target price of $33.79.
Acadia Healthcare Sets Q3 2026 Earnings Date. Acadia Healthcare announced the date for its third-quarter 2026 earnings release. This update provides a timeline for the next major financial report from the company. The stock is currently trading within its 52-week range of $11.43 to $35.83, with an average analyst target price of $33.79.